Routine clinical use of alemtuzumab in p
✍
Michael Fiegl; Andreas Falkner; Georg Hopfinger; Stefan Brugger; August Zabernig
📂
Article
📅
2006
🏛
John Wiley and Sons
🌐
English
⚖ 250 KB
👁 1 views
## Abstract ## BACKGROUND. In previous studies, alemtuzumab demonstrated considerable activity in patients with previously treated B‐cell chronic lymphocytic leukemia (CLL), including fludarabine‐refractory disease. In this retrospective study, the authors evaluated the benefit of alemtuzumab mono